sortilin related VPS10 domain containing receptor 2Genealiases: []
Q-omics provides the consensus-scored SORCS2 profile across patient tissues and cancer cell-line models. SORCS2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SORCS2 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SORCS2 protein abundance shows 22,369 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where SORCS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SORCS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SORCS2 survival associations across molecular data types. SORCS2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SORCS2 RNA expression–survival associations across cancer types. High SORCS2 expression shows unfavorable associations in ACC, STAD, OV and KIRC, but favorable associations in UCS and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SORCS2 RNA expression.
This table summarizes SORCS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SORCS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SORCS2 shows lower tumor expression in KIRC, LUAD, KIRP, LUSC and UCEC and higher tumor expression in HNSC. The KIRC box plot shows higher SORCS2 RNA expression in normal versus tumor tissue (log2 FC = −2.113, t-test p < 0.001).
This table shows molecular features associated with SORCS2 in patient tissues and cancer cell lines. In patient samples, SORCS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SORCS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
